Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Briere JB, Bowrin K, Coleman C, Fauchier L, Levy P, Folkerts K, Toumi M, Taieb V, Millier A, Wu O. Briere JB, et al. Among authors: bowrin k. Expert Rev Pharmacoecon Outcomes Res. 2019 Feb;19(1):27-36. doi: 10.1080/14737167.2018.1518134. Epub 2018 Sep 19. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 30169975
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Coleman CI, Briere JB, Fauchier L, Levy P, Bowrin K, Toumi M, Millier A, Taieb V, Wu O. Coleman CI, et al. Among authors: bowrin k. J Mark Access Health Policy. 2019 Feb 4;7(1):1574541. doi: 10.1080/20016689.2019.1574541. eCollection 2019. J Mark Access Health Policy. 2019. PMID: 30774786 Free PMC article.
Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB, Bowrin K, Millier A, Toumi M, Wojciechowski P, Taieb V. Briere JB, et al. Among authors: bowrin k. J Med Econ. 2019 Aug;22(8):760-765. doi: 10.1080/13696998.2019.1606001. Epub 2019 May 3. J Med Econ. 2019. PMID: 30969801 Free article.
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Briere JB, Wu O, Bowrin K, Millier A, Toumi M, Taieb V, Levy P, Coleman CI. Briere JB, et al. Among authors: bowrin k. Curr Med Res Opin. 2019 Nov;35(11):1867-1872. doi: 10.1080/03007995.2019.1647020. Epub 2019 Aug 13. Curr Med Res Opin. 2019. PMID: 31328580 Free article.
33 results